AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in TB
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in NTM
Number of subjects: 1226
Study 38001469 — intervention group
Group type: EXPERIMENTAL
Intervention: SLCO1B1 phenotypes in LTBI
Number of subjects: 1226
Study 38001473 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluative conditioning training with real tDCS over the orbitofrontal cortex
Number of subjects: 55
Study 38001473 — intervention group
Group type: COMPARATOR
Intervention: Evaluative conditioning training with sham tDCS over the orbitofrontal cortex
Number of subjects: 55
Study 38001473 — intervention group
Group type: COMPARATOR
Intervention: Sham evaluative conditioning training with real tDCS over the orbitofrontal cortex
Number of subjects: 55
Study 38001473 — intervention group
Group type: COMPARATOR
Intervention: Sham evaluative conditioning training with sham tDCS over the orbitofrontal cortex
Number of subjects: 55
Study 38001474 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (1000 mg fish oil, 13% EPA, 9% DHA) with glimepiride 3 mg
Number of subjects: 70
Study 38001474 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil and linoleic acid) with glimepiride 3 mg
Number of subjects: 70
Study 38001478 — intervention group
Group type: EXPERIMENTAL
Intervention: IAU + EBIS
Number of subjects: 40
Study 38001478 — intervention group
Group type: COMPARATOR
Intervention: IAU
Number of subjects: 40
Study 38001506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges to patients
Number of subjects: 1600
Study 38001506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges to clinicians
Number of subjects: 1600
Study 38001506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges to both patients and clinicians
Number of subjects: 1600
Study 38001506 — intervention group
Group type: COMPARATOR
Intervention: No nudges (neither)
Number of subjects: 1600
Study 38001507 — intervention group
Group type: EXPERIMENTAL
Intervention: Limiting ED rocuronium exposure (using succinylcholine as the default NMB)
Number of subjects: 3090
Study 38001507 — intervention group
Group type: COMPARATOR
Intervention: Control phase (observational conditions with rocuronium)
Number of subjects: 3090
Study 38001507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase (using succinylcholine as the default NMB)
Number of subjects: 3090
Study 38001507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 3090
Study 38001523 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE-CITE-Gait intervention (4-week duration, includes online video-based modules and two 2-hour home visits)
Number of subjects: 15
Study 38001540 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (VR) combined with standard early mobilization protocol
Number of subjects: 0
Study 38001540 — intervention group
Group type: COMPARATOR
Intervention: Standard early mobilization protocol (Control)
Number of subjects: 0
Study 38001544 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered Body Project groups led by clinicians
Number of subjects: 441
Study 38001544 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtually delivered Body Project groups led by peers
Number of subjects: 441
Study 38001544 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control group
Number of subjects: 441
Study 38001951 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild water-filtered infrared-A whole-body hyperthermia (wIRA-WBH)
Number of subjects: 0
Study 38002616 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine added to Bupivacaine
Number of subjects: 0
Study 38002616 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol added to Bupivacaine
Number of subjects: 0
Study 38002616 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (Control)
Number of subjects: 0
Study 38002635 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly thirty-minute exercise intervention
Number of subjects: 73
Study 38002635 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 73
Study 38004228 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine 2 g/day
Number of subjects: 49
Study 38004228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 38004269 — intervention group
Group type: EXPERIMENTAL
Intervention: Front-crawl swimming task
Number of subjects: 21
Study 38004269 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG metrics for 12 muscles
Number of subjects: 21
Study 38004546 — intervention group
Group type: EXPERIMENTAL
Intervention: New food-grade berberine delivery system (Berberine LipoMicel)
Number of subjects: 0
Study 38004546 — intervention group
Group type: COMPARATOR
Intervention: Standard berberine formulation
Number of subjects: 0
Study 38006001 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (vaccinated group)
Number of subjects: 643
Study 38006001 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated/not up-to-date (control group)
Number of subjects: 643
Study 38006237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 53
Study 38006237 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 53
Study 38006892 — intervention group
Group type: EXPERIMENTAL
Intervention: VV116 (0·6 g every 12 h on day 1 and 0·3 g every 12 h on days 2-5)
Number of subjects: 1347
Study 38006892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (on the same schedule as VV116)
Number of subjects: 1347
Study 38006908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy targeting systolic BP <130 mm Hg
Number of subjects: 128
Study 38006908 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy targeting systolic BP <140 mm Hg
Number of subjects: 128
Study 38006967 — intervention group
Group type: EXPERIMENTAL
Intervention: Early target temperature (TT) group (≤4 hours of age)
Number of subjects: 500
Study 38006967 — intervention group
Group type: COMPARATOR
Intervention: Late target temperature (TT) group (>4 hours of age)
Number of subjects: 500
Study 38006967 — intervention group
Group type: EXPERIMENTAL
Intervention: Early TT group (≤4 hours of age)
Number of subjects: 500
Study 38006967 — intervention group
Group type: COMPARATOR
Intervention: Late TT group (>4 hours of age)
Number of subjects: 500
Study 38006972 — intervention group
Group type: EXPERIMENTAL
Intervention: Berotralstat 150 mg once-daily monotherapy
Number of subjects: 34
Study 38007219 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line cryoablation
Number of subjects: 3
Study 38007349 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line trastuzumab with pertuzumab
Number of subjects: 225
Study 38007349 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line trastuzumab without pertuzumab
Number of subjects: 225
Study 38007349 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab pretreated patients
Number of subjects: 225
Study 38007586 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (starting dose: 500 mg/day)
Number of subjects: 156
Study 38007646 — intervention group
Group type: EXPERIMENTAL
Intervention: Gustatory evoked potentials (GEPs) in response to sucrose solution
Number of subjects: 45
Study 38007646 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive assessments and hormone levels (ghrelin, leptin, insulin, serotonin)
Number of subjects: 45
Study 38007648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Sensi® Chair (NSC) - 20 minutes per session, three times a week for 16 weeks
Number of subjects: 77
Study 38008001 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA2-MD
Number of subjects: 37
Study 38008001 — intervention group
Group type: EXPERIMENTAL
Intervention: SELENON-RM
Number of subjects: 37
Study 38008001 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 37
Study 38008001 — intervention group
Group type: EXPERIMENTAL
Intervention: SNIP
Number of subjects: 37
Study 38008031 — intervention group
Group type: EXPERIMENTAL
Intervention: Belzutifan 120 mg orally once daily until disease progression, unacceptable toxicity, or patient withdrawal.
Number of subjects: 55
Study 38008033 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidating high-dose therapy and autologous hematopoietic stem cell transplantation (HDT-ASCT) in partial response (PR) or better
Number of subjects: 243
Study 38008033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort I (synchronous SCNSL)
Number of subjects: 243
Study 38008033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort II (metachronous SCNSL)
Number of subjects: 243
Study 38008099 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (400 mg and 200 mg once-a-week intravenous)
Number of subjects: 294
Study 38008099 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (70 mg and 50 mg once-a-day intravenous)
Number of subjects: 294
Study 38008109 — intervention group
Group type: EXPERIMENTAL
Intervention: 72 mg ligelizumab
Number of subjects: 2057
Study 38008109 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg ligelizumab
Number of subjects: 2057
Study 38008109 — intervention group
Group type: COMPARATOR
Intervention: 300 mg omalizumab
Number of subjects: 2057
Study 38008109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2057
Study 38008305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levonorgestrel emergency contraception with same-day etonogestrel implant insertion
Number of subjects: 160
Study 38008698 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + exercise (LFN-exercise protocol)
Number of subjects: 27
Study 38008698 — intervention group
Group type: COMPARATOR
Intervention: Diet
Number of subjects: 27
Study 38008712 — intervention group
Group type: COMPARATOR
Intervention: Complex Training Group (CTG)
Number of subjects: 42
Study 38008712 — intervention group
Group type: COMPARATOR
Intervention: Plyometric Training Group (PTG)
Number of subjects: 42
Study 38008712 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 42
Study 38009088 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task (DT) conditions involving a secondary cognitive task (visual discrimination, attention task, mental arithmetic) during motor activities (overground walking, semi-tandem stance, isometric knee extension)
Number of subjects: 42
Study 38009088 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground walking in wide vs. narrow lane conditions
Number of subjects: 42
Study 38009088 — intervention group
Group type: EXPERIMENTAL
Intervention: Static and dynamic motor activities assessed with high-density surface electromyography and electroencephalography
Number of subjects: 42
Study 38009200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 0
Study 38009209 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38009241 — intervention group
Group type: EXPERIMENTAL
Intervention: donidalorsen 80 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 17
Study 38009241 — intervention group
Group type: EXPERIMENTAL
Intervention: donidalorsen 80 mg every 8 weeks (Q8W)
Number of subjects: 17
Study 38009241 — intervention group
Group type: EXPERIMENTAL
Intervention: donidalorsen
Number of subjects: 17
Study 38009310 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of systolic blood pressure variability (BPV)
Number of subjects: 13000
Study 38009310 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic BPV
Number of subjects: 13000
Study 38009310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BPV
Number of subjects: 13000
Study 38009546 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12-week, home-based intervention based on individual and family self-management theory.
Number of subjects: 60
Study 38009546 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Group (AC)
Number of subjects: 60
Study 38009575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh hernia repair
Number of subjects: 1241
Study 38009662 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (tremelimumab plus durvalumab)
Number of subjects: 61
Study 38009662 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (tremelimumab followed by durvalumab)
Number of subjects: 61
Study 38009933 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 52
Study 38009933 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine/Naloxone
Number of subjects: 52
Study 38009966 — intervention group
Group type: EXPERIMENTAL
Intervention: Active (anodal) transcranial direct current stimulation (tDCS) targeting the mPFC during exposure therapy
Number of subjects: 31
Study 38009966 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) during exposure therapy
Number of subjects: 31
Study 38009966 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (giving speeches to audiences in virtual reality)
Number of subjects: 31
Study 38010035 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized care for ADPKD including pain/depression screening, cardiac manifestations, liver and pancreatic cysts, kidney stone management, and genetic counseling.
Number of subjects: 0
Study 38010080 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention
Number of subjects: 43
Study 38010080 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 38010108 — intervention group
Group type: COMPARATOR
Intervention: SAR443820 (DNL788)
Number of subjects: 0
Study 38010254 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0892 (1 mg id)
Number of subjects: 51
Study 38010254 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0892 (4 mg im)
Number of subjects: 51
Study 38010254 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0892 (4 mg id)
Number of subjects: 51
Study 38010254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 38010254 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP0892
Number of subjects: 51
Study 38010261 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured social communication assessment (CSBS)
Number of subjects: 0
Study 38010261 — intervention group
Group type: COMPARATOR
Intervention: Naturalistic social communication assessment (MCX)
Number of subjects: 0
Study 38010260 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily (q.d.)
Number of subjects: 320
Study 38010260 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKIs (gefitinib 250 mg q.d. or erlotinib 150 mg q.d.)
Number of subjects: 320
Study 38010260 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed RECIST PFS for osimertinib
Number of subjects: 320
Study 38010260 — intervention group
Group type: COMPARATOR
Intervention: Observed RECIST PFS for comparator
Number of subjects: 320
Study 38010394 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day)
Number of subjects: 9
Study 38010430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic Esophagitis Impact Questionnaire (EoE-IQ)
Number of subjects: 239
Study 38010606 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b at 250 μg plus standard of care (SOC)
Number of subjects: 60
Study 38010606 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 60
Study 38010656 — intervention group
Group type: EXPERIMENTAL
Intervention: Video education on neonatal resuscitation options
Number of subjects: 0
Study 38010656 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38010661 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily for 52-week maintenance therapy
Number of subjects: 663
Study 38010661 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg once daily for 52-week maintenance therapy
Number of subjects: 663
Study 38010661 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 45 mg once daily for 16 weeks during induction therapy
Number of subjects: 663
Study 38010691 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT)
Number of subjects: 455
Study 38010691 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 455
Study 38010725 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk-reduction intervention (health coaching and nurse visits)
Number of subjects: 172
Study 38010725 — intervention group
Group type: COMPARATOR
Intervention: Health education control
Number of subjects: 172
Study 38010725 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized risk-reduction intervention
Number of subjects: 172
Study 38010758 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported Working Alliance Inventory (WAI) indicating a drop in alliance
Number of subjects: 58
Study 38010758 — intervention group
Group type: COMPARATOR
Intervention: Randomly chosen sessions from the same treatment phase
Number of subjects: 58
Study 38010773 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-person elevations in negative affect
Number of subjects: 92
Study 38010773 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect
Number of subjects: 92
Study 38011030 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Meditation Course
Number of subjects: 0
Study 38011129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preloaded combination nicotine replacement therapy (NRT)
Number of subjects: 200
Study 38011129 — intervention group
Group type: COMPARATOR
Intervention: Fast-acting nicotine replacement therapy (NRT) alone
Number of subjects: 200
Study 38011131 — intervention group
Group type: EXPERIMENTAL
Intervention: [68Ga]FAPI-46 PET
Number of subjects: 60
Study 38011131 — intervention group
Group type: EXPERIMENTAL
Intervention: [68Ga]FAPI-46 PET after neoadjuvant therapy (NAT)
Number of subjects: 60
Study 38011138 — intervention group
Group type: EXPERIMENTAL
Intervention: Three exercise modalities
Number of subjects: 280
Study 38011235 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg BID subcutaneous injection) for 5 days or until hospital discharge.
Number of subjects: 350
Study 38011235 — intervention group
Group type: COMPARATOR
Intervention: Standard care.
Number of subjects: 350
Study 38011235 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (5 µg BID subcutaneous injection).
Number of subjects: 350
Study 38011331 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioplasty guidewire-assisted transseptal puncture (TSP)
Number of subjects: 263
Study 38011331 — intervention group
Group type: COMPARATOR
Intervention: Conventional Brockenbrough needle TSP
Number of subjects: 263
Study 38011350 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training adaptations
Number of subjects: 25
Study 38011350 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP advertising adaptations
Number of subjects: 25
Study 38011350 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP safety information
Number of subjects: 25
Study 38011350 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-playing in training
Number of subjects: 25
Study 38011350 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of side effects information in advertisements
Number of subjects: 25
Study 38011420 — intervention group
Group type: EXPERIMENTAL
Intervention: edaravone
Number of subjects: 0
Study 38011420 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38011623 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous Telepsychiatry
Number of subjects: 0
Study 38011623 — intervention group
Group type: COMPARATOR
Intervention: Synchronous Telepsychiatry
Number of subjects: 0
Study 38011669 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional synthetic DMARDs in the UK (66.4%) vs continental Europe (44.9%)
Number of subjects: 503
Study 38011669 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic DMARDs in the UK (36.4%) vs continental Europe (64.4%)
Number of subjects: 503
Study 38011669 — intervention group
Group type: EXPERIMENTAL
Intervention: CollaboRATE scores ≥4.5
Number of subjects: 503
Study 38011669 — intervention group
Group type: COMPARATOR
Intervention: CollaboRATE scores <4.5
Number of subjects: 503
Study 38011669 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of collaboration in face-to-face PsA consultations
Number of subjects: 503
Study 38011669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild disease activity with higher perceived collaboration
Number of subjects: 503
Study 38011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 120
Study 38011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated intravenous (IV) fluids
Number of subjects: 120
Study 38011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated irrigation fluids
Number of subjects: 120
Study 38011688 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of forced-air warming and heated IV and irrigation fluids
Number of subjects: 120
Study 38011704 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vehicle HEPA filtration
Number of subjects: 14
Study 38011704 — intervention group
Group type: COMPARATOR
Intervention: On-road air exposure (control)
Number of subjects: 14
Study 38011739 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation-based lifestyle modification
Number of subjects: 0
Study 38011739 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38011750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-Commitment Therapy
Number of subjects: 0
Study 38011750 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38011922 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay
Number of subjects: 48282
Study 38011922 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay (reclassified patients)
Number of subjects: 48282
Study 38011922 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity cardiac troponin I assay (non-ischaemic myocardial injury)
Number of subjects: 48282
Study 38011968 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab (10 mg/kg) and Cetuximab (500, 400 or 300 mg/m2)
Number of subjects: 16
Study 38011967 — intervention group
Group type: EXPERIMENTAL
Intervention: Single text message (TM1)
Number of subjects: 200